Plasma glucagon suppressibility after oral glucose in obese subjects with normal and impaired glucose tolerance
- PMID: 6390086
- DOI: 10.1016/0026-0495(84)90089-1
Plasma glucagon suppressibility after oral glucose in obese subjects with normal and impaired glucose tolerance
Abstract
Blood glucose, plasma insulin, and glucagon responses after a 75 g oral glucose-tolerance test were assessed in 9 normal controls, 5 obese nondiabetics (ON), 5 obese nondiabetics with fasting hyperinsulinemia (obese "resistant" nondiabetics--OR), 9 obese with impaired glucose tolerance (O-IGT), and 9 nonobese insulin-dependent diabetics (IDD). Fasting plasma glucagon concentrations were significantly higher in all groups of patients in comparison to the normal controls. Insulin secretion, evaluated in all but the IDD, was similar to normal in the ON and increased in the OR and O-IGT. Normal glucagon suppression was observed in the lean controls and ON but not in OR, O-IGT, and IDD. We suggested that the resistance to glucagon suppression after glucose load in the OR and O-IGT in the presence of increased insulin response could be an indication that the A cell participates in the relative insulin insensitivity of these subjects.
Similar articles
-
Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus.Diabetes Res Clin Pract. 1992 Jan;15(1):97-102. doi: 10.1016/0168-8227(92)90074-2. Diabetes Res Clin Pract. 1992. PMID: 1541241
-
Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects.Diabetes Care. 1997 Oct;20(10):1562-8. doi: 10.2337/diacare.20.10.1562. Diabetes Care. 1997. PMID: 9314636
-
Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.Metabolism. 2005 Sep;54(9):1168-73. doi: 10.1016/j.metabol.2005.03.024. Metabolism. 2005. PMID: 16125528
-
Plasma level of glucagon-like peptide 1 in obese Egyptians with normal and impaired glucose tolerance.Arch Med Res. 2014 Jan;45(1):58-62. doi: 10.1016/j.arcmed.2013.10.012. Epub 2013 Dec 7. Arch Med Res. 2014. PMID: 24321596
-
Gastric inhibitory polypeptide release after oral glucose: relationship to glucose intolerance, diabetes mellitus, and obesity.J Clin Endocrinol Metab. 1982 Aug;55(2):329-36. doi: 10.1210/jcem-55-2-329. J Clin Endocrinol Metab. 1982. PMID: 7045154
Cited by
-
The human α cell in health and disease.J Endocrinol. 2023 Jun 19;258(1):e220298. doi: 10.1530/JOE-22-0298. Print 2023 Jul 1. J Endocrinol. 2023. PMID: 37114672 Free PMC article. Review.
-
Postprandial Dynamics of Proglucagon Cleavage Products and Their Relation to Metabolic Health.Front Endocrinol (Lausanne). 2022 Jun 29;13:892677. doi: 10.3389/fendo.2022.892677. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35872982 Free PMC article. Clinical Trial.
-
Effect of free fatty acids on insulin secretion, insulin sensitivity and incretin effect - a narrative review.Arch Endocrinol Metab. 2021 Nov 1;65(1):24-31. doi: 10.20945/2359-3997000000313. Epub 2020 Dec 15. Arch Endocrinol Metab. 2021. PMID: 33320449 Free PMC article. Review.
-
Postprandial levels of GLP-1, GIP and glucagon after 2 years of weight loss with a Paleolithic diet: a randomised controlled trial in healthy obese women.Eur J Endocrinol. 2019 Jun 1;180(6):417-427. doi: 10.1530/EJE-19-0082. Eur J Endocrinol. 2019. PMID: 31042670 Free PMC article. Clinical Trial.
-
Metabolic effects of glucagon in humans.J Clin Transl Endocrinol. 2018 Dec 20;15:45-53. doi: 10.1016/j.jcte.2018.12.005. eCollection 2019 Mar. J Clin Transl Endocrinol. 2018. PMID: 30619718 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
